Genistein Combined with FOLFOX or FOLFOX-Avastin for treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study

ID Number 13-1697

Principal Investigator(s)
Randall Holcombe

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to determine if the addition of genistein, a natural product derived from soy will increase the chance of responding to chemotherapy (treatment of disease using drugs) for colon and rectal (colorectal) cancer.  There is evidence from laboratory studies that genistein blocks a pathway in the cancer cell that is necessary for its growth, and also that it may improve the effectiveness of chemotherapy such as 5-fluorouracil (5FU) and oxaliplatin.


One may qualify to take part in this research study because you have colon or rectal cancer which has recurred (come back) or spread to other parts of the body (metastatic) and because your oncologist (cancer specialist) is planning to provide chemotherapy called FOLFOX or FOLFOX with Avastin for treatment of this condition.  These are two standard approaches to the treatment of colorectal cancer and these chemotherapy combinations include 5FU and oxaliplatin.

Contact Information
(212) 824-7309

Recruiting Patients: Yes